Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 Bronchodilatory Effect in COPD
NCT00856193Phase 2Completed
- Sponsor
- Novartis
- Start
- Feb 2009
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of glycopyrronium in chronic obstructive pulmonary disease (COPD), sponsored by Novartis. Started Feb 2009; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00856193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856193.